Veru Inc (VERU)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $35.64M
Last updated: Nov 17, 2026 at 11:04 AM ET
Veru Inc (VERU) Earnings: Report Dates and Results
VERU is expected to report earnings on Dec 15, 2026. In the quarter ended Jun 30, 2026, VERU reported EPS of -$0.30, above the -$0.32 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VERU has an expected report date of Dec 15, 2026.
VERU Earnings Call
The latest VERU earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 37 quarters below that had an estimate, VERU beat 17, missed 18 and matched 2. The widest gap in the table came in the quarter ended Dec 31, 2018, when EPS landed 650.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.30 | -$0.32 | -$0.34 - -$0.30 | +6.25% | Beat | N/A | 2 | 1 up, 1 down | Aug 10, 2026 | N/A |
| Mar 31, 2026 | -$0.13 | -$0.28 | -$0.37 - -$0.20 | +53.57% | Beat | N/A | 2 | 0 up, 0 down | May 13, 2026 | N/A |
| Dec 31, 2025 | -$0.26 | -$0.47 | -$0.63 - -$0.31 | +44.68% | Beat | N/A | 2 | 0 up, 0 down | Feb 11, 2026 | N/A |
| Sep 30, 2025 | $0.09 | -$0.06 | N/A | +258.73% | Beat | N/A | 1 | 0 up, 1 down | Dec 17, 2025 | $247064 |
| Jun 30, 2025 | -$0.53 | -$0.50 | -$0.50 - -$0.50 | -6.00% | Miss | N/A | 2 | 0 up, 0 down | Aug 12, 2025 | N/A |
| Mar 31, 2025 | -$0.60 | -$0.50 | -$0.50 - -$0.50 | -20.00% | Miss | N/A | 1 | 0 up, 0 down | May 8, 2025 | N/A |
| Dec 31, 2024 | -$0.71 | -$0.80 | -$0.80 - -$0.80 | +11.25% | Beat | N/A | 1 | 0 up, 0 down | Feb 13, 2025 | N/A |
| Sep 30, 2024 | -$0.05 | -$0.08 | -$0.08 - -$0.08 | +35.00% | Beat | N/A | 1 | 0 up, 0 down | Dec 16, 2024 | $6.66M |
| Jun 30, 2024 | -$0.76 | -$0.60 | -$0.70 - -$0.50 | -26.67% | Miss | N/A | 5 | 0 up, 0 down | Aug 8, 2024 | N/A |
| Mar 31, 2024 | -$0.91 | -$1.50 | N/A | +39.33% | Beat | N/A | 3 | 2 up, 0 down | Apr 1, 2024 | N/A |
| Dec 31, 2023 | -$0.08 | -$0.10 | -$0.15 - -$0.08 | +20.00% | Beat | N/A | 3 | 0 up, 0 down | Feb 14, 2024 | N/A |
| Sep 30, 2023 | -$1.37 | -$2.35 | -$2.70 - -$2.00 | +41.70% | Beat | N/A | 2 | 0 up, 0 down | Dec 8, 2023 | $3.86M |
| Jun 30, 2023 | -$1.24 | -$2.90 | -$2.90 - -$1.20 | +57.24% | Beat | N/A | 2 | 0 up, 0 down | Aug 10, 2023 | $3.34M |
| Mar 31, 2023 | -$4.32 | -$3.30 | -$3.50 - -$3.10 | -30.91% | Miss | N/A | 4 | 0 up, 0 down | May 11, 2023 | $6.59M |
| Dec 31, 2022 | -$4.60 | -$3.77 | -$4.10 - -$3.40 | -22.02% | Miss | N/A | 3 | 0 up, 0 down | Feb 9, 2023 | $2.51M |
| Sep 30, 2022 | -$0.51 | -$0.30 | -$0.34 - -$0.27 | -70.00% | Miss | N/A | 5 | 0 up, 0 down | Dec 5, 2022 | $2.59M |
| Jun 30, 2022 | -$2.80 | -$1.64 | N/A | -70.73% | Miss | N/A | N/A | 0 up, 0 down | Aug 11, 2022 | $9.60M |
| Mar 31, 2022 | -$1.80 | -$1.15 | -$2.60 - -$0.80 | -56.52% | Miss | N/A | 4 | 0 up, 0 down | May 12, 2022 | $13.03M |
| Dec 31, 2021 | -$0.80 | -$0.67 | -$2.30 - -$0.60 | -19.40% | Miss | N/A | 4 | 0 up, 0 down | Feb 9, 2022 | $14.14M |
| Sep 30, 2021 | -$0.05 | -$0.09 | -$0.13 - -$0.06 | +44.44% | Beat | -266.7% | 5 | 2 up, 1 down | Dec 2, 2021 | $15.65M |
| Jun 30, 2021 | -$0.30 | -$0.60 | -$0.80 - -$0.50 | +50.00% | Beat | N/A | 5 | N/A | Aug 12, 2021 | $17.66M |
| Mar 31, 2021 | -$0.40 | -$0.30 | -$0.70 - -$0.20 | -33.33% | Miss | N/A | 5 | N/A | May 12, 2021 | $13.34M |
| Dec 31, 2020 | -$0.20 | -$0.40 | -$0.80 - -$0.20 | +50.00% | Beat | N/A | 3 | N/A | Feb 10, 2021 | $14.62M |
| Sep 30, 2020 | $0.03 | -$0.04 | -$0.04 - -$0.03 | +175.00% | Beat | N/A | 3 | N/A | Dec 9, 2020 | $11.75M |
| Jun 30, 2020 | -$0.50 | -$0.32 | -$0.40 - -$0.20 | -56.25% | Miss | N/A | 3 | N/A | Aug 13, 2020 | $10.32M |
| Mar 31, 2020 | -$0.10 | -$0.33 | -$0.70 - -$0.20 | +69.70% | Beat | N/A | 4 | N/A | May 13, 2020 | $9.94M |
| Dec 31, 2019 | -$0.50 | -$0.23 | -$0.50 - $0.00 | -117.39% | Miss | N/A | 3 | N/A | Feb 12, 2020 | $10.58M |
| Sep 30, 2019 | -$0.05 | -$0.05 | -$0.06 - -$0.04 | 0.00% | In line | N/A | 4 | N/A | Dec 12, 2019 | $8.73M |
| Jun 30, 2019 | -$0.40 | -$0.45 | -$0.50 - -$0.40 | +11.11% | Beat | N/A | 4 | N/A | Aug 8, 2019 | $9.73M |
| Mar 31, 2019 | -$0.60 | -$0.60 | -$0.80 - -$0.40 | 0.00% | In line | N/A | 4 | N/A | May 15, 2019 | $6.98M |
| Dec 31, 2018 | -$0.30 | -$0.04 | -$0.08 - $0.00 | -650.00% | Miss | N/A | 2 | N/A | Feb 13, 2019 | $6.37M |
| Sep 30, 2018 | -$0.14 | -$0.08 | N/A | -75.00% | Miss | N/A | N/A | N/A | Dec 13, 2018 | $5.20M |
| Jun 30, 2018 | -$1.50 | -$0.80 | -$1.10 - -$0.40 | -87.50% | Miss | N/A | 4 | N/A | Aug 14, 2018 | $5.50M |
| Mar 31, 2018 | -$0.70 | -$0.50 | -$0.80 - -$0.20 | -40.00% | Miss | N/A | 2 | N/A | May 9, 2018 | $2.57M |
| Dec 31, 2017 | -$0.40 | -$0.30 | -$0.30 - -$0.30 | -33.33% | Miss | N/A | 1 | N/A | Jan 2, 2018 | $2.59M |
| Jun 30, 2017 | -$0.30 | -$0.80 | N/A | +62.50% | Beat | -1630.6% | N/A | N/A | Aug 8, 2017 | $4.31M |
| Mar 31, 2017 | -$0.06 | -$0.04 | N/A | -50.00% | Miss | -5100.0% | N/A | N/A | May 9, 2017 | $2.41M |
| Dec 31, 2016 | -$0.04 | N/A | N/A | N/A | N/A | -185.8% | N/A | N/A | Feb 9, 2017 | $3.24M |
| Sep 30, 2016 | -$0.06 | N/A | N/A | N/A | N/A | -348.6% | N/A | N/A | Dec 12, 2016 | $3.56M |
| Jun 30, 2016 | $0.02 | N/A | N/A | N/A | N/A | -51.8% | N/A | N/A | Jul 28, 2016 | $5.56M |
Annual EPS
EPS for the fiscal year ended Sep 30, 2026 was -$0.69, after -$1.75 the year before. It was $0.01 for the year ended Sep 30, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | -$0.69 | N/A |
| Sep 30, 2025 | -$1.75 | N/A |
| Sep 30, 2024 | -$1.80 | N/A |
| Sep 30, 2023 | -$11.53 | N/A |
| Sep 30, 2022 | -$5.91 | N/A |
| Sep 30, 2021 | -$0.95 | N/A |
| Sep 30, 2020 | -$1.07 | N/A |
| Sep 30, 2019 | -$1.35 | N/A |
| Sep 30, 2018 | -$3.14 | -26744.9% |
| Sep 30, 2016 | $0.01 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,300 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 4,332 | 6 | |
| 2026Q1 | Mar 31, 2026 | 3,452 | 5 | |
| 2025Q4 | Dec 31, 2025 | 4,731 | 6 | |
| 2025Q3 | Sep 30, 2025 | 6,039 | 11 | |
| 2025Q2 | Jun 30, 2025 | 6,107 | 10 | |
| 2025Q1 | Mar 31, 2025 | 6,148 | 9 | |
| 2024Q2 | Jun 30, 2024 | 7,336 | 9 |
2026Q2 Earnings Call
Opening remarks
Sam Fisch Executive Director, Investor Relations and Corporate Communications The statements made on this conference call may be forward-looking statements. Forward-looking statements may include, but are not necessarily limited to, statements of the company's plans, objectives, expectations or intentions regarding its business, operations, regulatory interactions, finances and development and product portfolio. Such forward-looking statements are subject to known and unknown risks and uncertainties, and our actual results may differ significantly from those projected, suggested or included in any forward-looking statements. Risks that may cause actual results or developments to differ materially are contained in our 10-Q and 10-K SEC filings as well as in our press releases from time to time. I would now like to turn the conference call over to Dr. Mitchell Steiner, Veru Inc.'s Chairman, CEO and President.
Mitchell Steiner Chairman, CEO and President Good morning. With me on this morning's call are Dr. Gary Barnette, the Chief Scientific Officer; Michelle Greco, the Chief Financial Officer and Chief Administrative Officer; Phil Greenberg, General Counsel; and Sam Fisch, the Executive Director of Investor Relations and Corporate Communications. Thank you for joining our second quarter fiscal year 2026 earnings call. Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. Our drug development program consists of two novel small molecules, enobosarm and sabizabulin. The first one, enobosarm, is an oral selective androgen receptor modulator, SARM, and is being developed as a next-generation drug that when combined with a GLP-1 receptor agonist makes weight reduction more tissue selective for fat loss and preservation of lean mass and physical function, which is intended to lead to greater weight loss compared to GLP-1 receptor agonist treatment alone, with a focus on older patients with obesity. Our second asset, sabizabulin, is a microtubule disruptor and it's being developed as a broad anti-inflammatory agent to reduce vascular plaque inflammation to slow the progression or promote the regression of atherosclerotic cardiovascular disease. This morning, we'll focus on an update of the clinical development progress of enobosarm in our obesity program. We will also provide financial highlights for fiscal 2026 second quarter ended March 31, 2026. GLP-1 receptor agonists have been shown to produce significant weight loss in patients who are overweight or have obesity. Unfortunately, this weight loss is tissue nonselective with significant indiscriminate loss of both lean mass and fat mass. Of the total weight loss, up to 50% is attributable to lean mass. Although GLP-1 receptor agonist treatments have resulted in substantial weight loss for many patients, the strategy for the next generation of obesity drugs should be a combination therapy with a GLP-1 receptor agonist to cause weight reduction while preserving lean mass and physical function and bone mineral density with the highest quality weight reduction.
Frequently Asked Questions About VERU
When is VERU's next earnings date?
VERU's next earnings report is expected for Dec 15, 2026.
Did VERU beat earnings estimates last quarter?
Yes. VERU reported EPS of -$0.30 for the quarter ended Jun 30, 2026, above the -$0.32 estimate, a 6.25% surprise.
What EPS do analysts expect from VERU next quarter?
The consensus EPS estimate for VERU for the quarter ended Sep 30, 2026 is -$0.31 from 5 analysts, with estimates from -$0.33 to -$0.27.
How often does VERU beat earnings estimates?
VERU beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +47.94%.
VERU pages: Overview, Earnings, Forecast, Financials, Competitors